Niraparib (hydrochloride)

[1]Jones P, et al. Discovery of 2-{4-[ (3S) -piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827) : a novel oral poly (ADP-ribose) polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J Med Chem. 2009 Nov 26;52 (22) :7170-85.|[2]Bridges KA, et al. Niraparib (MK-4827), a novel poly (ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 2014 Jul 15;5 (13) :5076-86.|[3]Wang L, et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 2012 Dec;30 (6) :2113-20.|[4]Mirza MR, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Dec 1;375 (22) :2154-2164.

Int J Biol Macromol. 2024 May 9:132275.|J Oncol. 2022 Apr 5;2022:2800488.|Acta Pharm Sin B. 2025 Oct 1.|Adv Sci (Weinh) . 2022 Oct;9 (30) :e2201210.|Adv Sci (Weinh) . 2025 Jul 16:e15585.|Am J Cancer Res. 2024 Jan 15;14 (1) :378-389.|Am J Pathol. 2024 Nov;194 (11) :2007-2022.|Appl Microbiol Biotechnol. 2019 Dec;103 (23-24) :9557-9568.|Biochem Pharmacol. 2025 May:235:116843.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Pharmacother. 2025 Jun 16:189:118273.|bioRxiv. 2024 Jul 10:2024.07.09.602803.|bioRxiv. 2025 April 26.|bioRxiv. 2025 January 14.|bioRxiv. 2025 July 08.|BMC Cancer. 2022 Mar 23;22 (1) :312.|BMC Cancer. 2024 Dec 20;24 (1) :1562.|Cancer Cell. 2020 Dec 14;38 (6) :844-856.e7.|Cancer Chemother Pharmacol. 2017 Oct;80 (4) :861-867.|Cancer Discov. 2017 Sep;7 (9) :984-998.|Cancer Lett. 2022 Feb 1:526:180-192.|Cancer Res Commun. 2024 May 20.|Cancer Res. 2022 Jul 5;82 (13) :2361-2377.|Cancers (Basel) . 2023 May 11;15 (10) :2708.|Cancers (Basel) . 2024 Nov 5;16 (22) :3728.|Carcinogenesis. 2020 May 14;41 (3) :345-357.|Cell Death Dis. 2020 Apr 6;11 (4) :219.|Clin Cancer Res. 2017 Feb 15;23 (4) :1001-1011. |DNA Repair. 2019 Jan:73:64-70.|Drug Resist Updat. 2026 Jan:84:101319.|EBioMedicine. 2020 Sep;59:102923.|Elife. 2021 Jun 23:10:e69454.|Elife. 2022 Apr 27;11:e72464.|Faculty of Biology, University of Belgrade. 2019 Aug.|Front Oncol. 2021 Jul 9:11:681441.|HAL. archives-ouvertes. 2020 Dec 4.|Int Immunopharmacol. 2025 Sep 23:162:115158.|Int J Biol Sci. 2020 Feb 21;16 (8) :1363-1375.|Int J Cancer. 2025 Jan 15;156 (2) :389-402.|Int J Mol Sci. 2025 Mar 24;26 (7) :2921.|J Clin Invest. 2019 Mar 1;129 (3) :1211-1228.|J Exp Clin Cancer Res. 2025 Jun 16;44 (1) :175.|J Med Chem. 2024 Feb 22;67 (4) :2349-2368.|J Oncol. 2022 Apr 5;2022:2800488.|J Transl Med. 2025 Aug 5;23 (1) :860.|JCI Insight. 2023 Nov 8;8 (21) :e165268.|Life Sci Alliance. 2021 Oct 5;4 (12) :e202101144.|Mater Today Bio. 2020 Oct 22;8:100082.|medRxiv. 2020 Jan.|Mol Cancer Ther. 2023 Apr 3;22 (4) :447-458.|Mol Pharm. 2021 Dec 6;18 (12) :4371-4384.|Nat Biomed Eng. 2024 Feb;8 (2) :165-176.|Nat Commun. 2022 Nov 19;13 (1) :7107.|Neurooncol Adv. 2024 Nov 19;6 (1) :vdae187.|NPJ Precis Oncol. 2021 Jun 9;5 (1) :49.|NPJ Precis Oncol. 2025 Aug 30;9 (1) :306.|Nucl Med Biol. 2016 Dec;43 (12) :752-758. |Oncogene. 2022 Sep;41 (37) :4271-4281.|Patent. US20170226063A1.|Patent. US20180134664A1.|Patent. US20180362972A1.|Patent. US20190092732A1.|Patent. US20200078369A1|Patent. US20200129476A1|Patent. US20200148645A1|Patent. US20220048863A1.|Patent. US9932310B2.|PeerJ. 2023 Nov 29:11:e16314.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2024 Nov 06.|Sci Adv. Sci Adv. 2025 Apr 25;11 (17) :eadu0847.|Sci Rep. 2021 Sep 27;11 (1) :19138.|Theranostics. 2020 Jul 25;10 (21) :9477-9494. |Uppsala University. Department of Pharmaceutical Biosciences. 2022 Feb.|Urol Oncol. 2025 Sep 30:S1078-1439 (25) 00359-X.|J Med Chem. 2023 Mar 23;66 (6) :4106-4130.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20210299137A1.